Ridazolol
Names | |
---|---|
IUPAC name 5-Chloro-4-[2-[[3-(2-chlorophenoxy)-2-hydroxypropyl]amino]ethylamino]-1H-pyridazin-6-one | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C15H18Cl2N4O3 | |
Molar mass | 373.23 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Ridazolol is a pharmaceutical drug acting as a beta adrenergic receptor antagonist. It was investigated in the 1980 and 90s for its effects on coronary heart disease and essential hypertension (high blood pressure).[1][2]
It is not known to be marketed anywhere in the world.[3]
References
- ^ Fach, WA; Starke, E; Becker, HJ (1992). "Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease". Zeitschrift für Kardiologie. 81 (6): 320–5. PMID 1353933.
- ^ Rommel, Th.; Demisch, L. (1994). "Influence of chronic ?-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension". Journal of Neural Transmission. 95 (1): 39–48. doi:10.1007/BF01283029. PMID 7857585. S2CID 31936176.
- ^ "Ridazolol search results". Drugs.com. Retrieved 2021-03-31.